Tonix Pharmaceuticals | DEF 14A: Definitive information statements
Tonix Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Holding Corp. Announced the Presentation of Additional Efficacy Data from the Phase 3 Resilient Study
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime Tnx-102 Sl on Ptsd Symptoms and Sleep Quality in Military-Related Ptsd at Four Weeks of Therapy
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 in Healthy Volunteers
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China
Tonix Pharmaceuticals | 8-K: Poll Results of Tonix Pharmaceuticals Meeting
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Increase the Number of Authorized Shares of the Company's Common Stock from 160,000,000 to 1,000,000,000 Shares
No Data